Pfizer and BioNech announced on Thursday that a third booster vaccine increases immune defenses against COVID-19 in children ages 5 to 11, particularly against the Omicron variant.
Pfizer and BioNTech said that blood serum analysis of a few pediatric participants who received a booster dose in a study showed a 36-fold increase in Omicron neutralizing antibodies.
According to Pfizer and BioNTech, neutralizing antibodies against SARS-CoV-2 wild-type strain rose six-fold following the booster shot.
The study from Pfizer and BioNTech tested the safety and immunogenicity of a 10-microgram booster dose in 140 healthy children aged 5 through 11 years.
Pfizer and BioNTech said the data reinforces the potential function of a third dose of the vaccine in maintaining high protection against the virus in this age group.
Pfizer and BioNTech will request authorization for a booster dose in the 5-11 age group in the coming days, with additional submissions to global regulatory agencies, including the European Medicines Agency.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.